Equities

Kangmei Pharmaceutical Co Ltd

600518:SHH

Kangmei Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)2.52
  • Today's Change-0.14 / -5.26%
  • Shares traded1.38bn
  • 1 Year change+34.04%
  • Beta--
Data delayed at least 15 minutes, as of Nov 13 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments9561,4322,345
Total Receivables, Net2,9692,9352,493
Total Inventory2,6442,7513,195
Prepaid expenses136189156
Other current assets, total1057796
Total current assets6,8107,3848,285
Property, plant & equipment, net3,8964,1944,668
Goodwill, net106106106
Intangibles, net491530580
Long term investments2,8082,7702,244
Note receivable - long term------
Other long term assets----0.03
Total assets14,28015,16916,054
LIABILITIES
Accounts payable2,2052,5332,015
Accrued expenses7441,2721,195
Notes payable/short-term debt1,0321,01730
Current portion long-term debt/capital leases413937
Other current liabilities, total6585811,670
Total current liabilities4,6805,4424,947
Total long term debt188199153
Total debt1,2611,255220
Deferred income tax5256--
Minority interest333542
Other liabilities, total2,2802,489986
Total liabilities7,2338,2206,128
SHAREHOLDERS EQUITY
Common stock13,86413,86413,864
Additional paid-in capital18,78318,78318,783
Retained earnings (accumulated deficit)(24374)(24477)(21787)
Treasury stock - common(1225)(1222)(933)
Unrealized gain (loss)0.150.39--
Other equity, total(0.25)(0.26)(0.27)
Total equity7,0486,9489,927
Total liabilities & shareholders' equity14,28015,16916,054
Total common shares outstanding13,78813,78813,788
Treasury shares - common primary issue767676
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.